How Does Cencora Stock Stack Up Against Its Peers?
Cencora‘s stock has outperformed many peers over the past year, but how does it truly stack up against key distributors? As of December 2, 2025, a closer look reveals solid revenue growth and moderate operating margins, yet a higher valuation and lower free cash flow efficiency. Its upside may be limited if peers with stronger profitability and lower P/E ratios continue to attract investor preference. Cencora, formerly known as AmerisourceBergen until its 2023 rebranding, is a global pharmaceutical distribution company that connects manufacturers with healthcare providers, also offering logistics, data analytics, and consulting services.
- COR’s 1.2% operating margin, trailing HSIC (5.9%), reflects the tight profitability inherent in pharmaceutical distribution.
- COR’s 11.6% LTM revenue growth, strong vs. CAH, HSIC but lags MCK, OMI, reflecting varied specialty pharma and home healthcare market exposures.
- COR’s 41.4% stock gain and 30.6 PE, despite CAH’s stronger returns, signals high investor confidence in future specialty pharma growth.
Here’s how Cencora stacks up across size, valuation, and profitability versus key peers.
| COR | CAH | MCK | HSIC | OMI | |
|---|---|---|---|---|---|
| Market Cap ($ Bil) | 68.0 | 48.8 | 102.9 | 8.6 | 0.2 |
| Revenue ($ Bil) | 316.7 | 222.6 | 387.1 | 12.9 | 12.7 |
| PE Ratio | 30.6 | 23.9 | 23.8 | 20.4 | -0.3 |
| LTM Revenue Growth | 11.6% | -1.9% | 17.2% | 3.5% | 92.4% |
| LTM Operating Margin | 1.2% | 1.0% | 1.4% | 5.9% | 2.6% |
| LTM FCF Margin | 0.4% | 0.8% | 1.6% | 2.8% | -2.8% |
| 12M Market Return | 41.4% | 69.9% | 34.1% | -6.3% | -81.0% |
For more details on Cencora, read Buy or Sell COR Stock. Below we compare COR’s growth, margin, and valuation with peers across years
Revenue Growth Comparison
- Can Tesla Stock’s $1.3T Valuation Withstand China’s Humanoid Surge?
- Tempus AI Stock: Why The AI Oncology Platform Is Worth Paying Up For
- Apple’s $14B Capex in a $700B AI World: Smart or Shortsighted?
- What Could Rocket Broadcom Stock to New Heights
- Can NVIDIA Stock Withstand These Pressures?
- Could FactSet Research Systems Stock’s Cash Flow Spark the Next Rally?
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| COR | 11.6% | – | 12.1% | 9.9% | 11.5% |
| CAH | -1.9% | -1.9% | 10.7% | 13.0% | |
| MCK | 17.2% | 16.2% | 11.7% | 4.8% | |
| HSIC | 3.5% | – | 2.7% | -2.4% | 2.0% |
| OMI | 92.4% | – | 3.6% | 3.8% | 1.7% |
Operating Margin Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| COR | 1.2% | – | 1.1% | 1.0% | 1.2% |
| CAH | 1.0% | 1.0% | 0.9% | 0.9% | |
| MCK | 1.4% | 1.3% | 1.4% | 1.7% | |
| HSIC | 5.9% | – | 5.8% | 5.6% | 6.9% |
| OMI | 2.6% | – | 2.8% | 2.9% | 2.8% |
PE Ratio Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| COR | 30.6 | – | 29.6 | 23.8 | 20.3 |
| CAH | 23.9 | 18.3 | 29.0 | 60.8 | |
| MCK | 23.8 | 22.0 | 20.5 | 14.9 | |
| HSIC | 20.4 | – | 22.5 | 23.8 | 20.2 |
| OMI | -0.3 | – | -2.8 | -35.4 | 65.0 |
Still not sure about COR stock? Consider portfolio approach.
Portfolios Win When Stock Picks Fall Short
Individual picks can be volatile but staying invested is what matters. A diversified portfolio helps you stay the course, capture upside and reduce downside
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.